Eli Lilly signs $415m deal for Alchemab’s ALS therapy
The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.
Neurology
Biohaven secures $600m financing as it awaits FDA prodrug decision
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
Tempero secures $70m to advance addiction treatment candidate
Augustine secures $85m to advance Charcot-Marie-Tooth candidate
SmartCella gains rights to advance cell therapy research for Parkinson’s
